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available and critical need for specific histopathological mark-
ers. Here, we analyzed formalin-fixed paraffin-embedded tis-
sues from 143 pediatric HGA and 297 other primary brain 
tumors or normal brain. Immunohistochemical staining for 
H3K27M was compared to tumor genotype, and also com-
pared to H3 tri-methylated lysine 27 (H3K27me3) staining, 
previously shown to be drastically decreased in samples car-
rying this mutation. There was a 100 % concordance between 
genotype and immunohistochemical analysis of H3K27M in 
tumor samples. Mutant H3K27M was expressed in the major-
ity of tumor cells, indicating limited intra-tumor heterogene-
ity for this specific mutation within the limits of our dataset. 
Both H3.1 and H3.3K27M mutants were recognized by this 
Abstract Studies in pediatric high-grade astrocytomas 
(HGA) by our group and others have uncovered recurrent 
somatic mutations affecting highly conserved residues in his-
tone 3 (H3) variants. One of these mutations leads to analo-
gous p.Lys27Met (K27M) mutations in both H3.3 and H3.1 
variants, is associated with rapid fatal outcome, and occurs 
specifically in HGA of the midline in children and young 
adults. This includes diffuse intrinsic pontine gliomas (80 %) 
and thalamic or spinal HGA (>90 %), which are surgically 
challenging locations with often limited tumor material 
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antibody while non-neoplastic elements, such as endothelial 
and vascular smooth muscle cells or lymphocytes, did not 
stain. H3K27me3 immunoreactivity was largely mutually 
exclusive with H3K27M positivity. These results demon-
strate that mutant H3K27M can be specifically identified with 
high specificity and sensitivity using an H3K27M antibody 
and immunohistochemistry. Use of this antibody in the clini-
cal setting will prove very useful for diagnosis, especially in 
the context of small biopsies in challenging midline tumors 
and will help orient care in the context of the extremely poor 
prognosis associated with this mutation.
Keywords K27M · Histone 3 variants · IHC · K27 
trimethylation · High-grade astrocytomas
Introduction
Recent years have seen an explosion of genomic data across 
many types of human cancer including high-grade gliomas, 
through the increasing use of next generation sequencing 
(NGS) technologies and efforts of independent laboratories, 
as well as large consortia such as The Cancer Genome Atlas 
(TCGA) and the International Cancer Genome Consortium 
(ICGC). In children and young adults, critical epigenetic alter-
ations were discovered in subgroups of these tumors. Somatic 
recurrent mutations resulting in amino acid substitutions at 
lysine 27 (p.Lys27Met, K27M) and glycine 34 (p.Gly34Arg/
Val, G34R/V) in H3F3A, which encodes histone 3 (H3) vari-
ant 3 (H3.3), were shown by our group and others to charac-
terize about one-third of pediatric high-grade astrocytomas 
(HGA) [20, 24]. These mutations resulted in somatic het-
erozygous lysine 27 to methionine (p.Lys27Met, K27M) and 
glycine 34 to arginine or valine (p.Gly34Arg/Val, G34R/V) 
amino acid substitutions at these positions within the H3.3 tail 
[20, 24]. A large cohort of 784 gliomas of all ages and his-
topathological grades (WHO I–IV) confirmed the prevalence 
of H3F3A mutations in pediatric and young adult HGA [20] 
as did additional studies performed by other groups [9, 26]. 
Genomic analysis of HGA and correlation of results with age 
and tumor site showed that H3.3G34R/V mutations character-
ize HGA located within the cerebral hemispheres, mainly tem-
poro-parietal regions in adolescents and young adults with this 
tumor [12, 21]. K27M mutations in H3.3 and histone variant 
H3.1 (encoded by HIST1H3B) were also shown to be present 
in 71–78 % of diffuse intrinsic pontine gliomas (DIPGs), 
which are HGA of the pons [12, 24]. Moreover, H3F3A 
K27M mutations also characterize pediatric [8, 20, 21] and 
younger adult HGA [1] arising in the thalamus, the spinal cord 
or the cerebellum [8, 21] thus confirming preponderance of 
H3K27M mutations in HGA in the midline [12, 20, 21, 24]. 
These brain regions are notoriously difficult areas for surgical 
resection and stereotactic biopsy and the frequency and speci-
ficity of these mutations in histones strongly support their use 
in diagnosis and as biomarkers for these HGA tumors in chil-
dren and younger patients [3, 4, 8, 22, 25].
The current routine procedure for assessing H3 status 
is through DNA sequencing. This is a time-consuming 
and laborious process which requires extraction of nucleic 
acids and relatively elaborate laboratory equipment that 
may not be available in every pathology department. In 
contrast, immunohistochemistry (IHC) is routinely per-
formed in pathology laboratories. Critical insight into the 
effects of the K- to M change in H3 tails was provided by 
the Allis group who showed that this mutation acted as a 
gain-of-function through inhibition of the methyltrans-
ferase activity of EZH2 [14]. This leads to decreased lev-
els of K27me3 because the Polycomb repressive complex 
2 which contains EZH2 is unable to mediate this activity 
in the presence of H3K27M [14]. Decreased H3K27me3 
levels in H3K27M-mutant HGA samples were shown by 
several groups further confirming this effect on tumor tis-
sues [2, 23]. Therefore, use of decreased H3K27me3 lev-
els by IHC was proposed as a surrogate marker to diagnose 
H3.3K27M mutation in the clinical setting [23]. However, 
the normal pattern of H3K27me3 in control brain and other 
brain tumors is not clearly established, and the availability 
of a mutation-specific antibody that specifically recognizes 
the mutation similar to the one derived for the most com-
mon isocitrate dehydrogenase (IDH) mutation in gliomas 
(IDH1R132H) would greatly help clinical management 
[5]. This is especially true in the context of the very poor 
outcome established for this specific mutation compared to 
H3.3 G34R/V mutations, IDH mutations, or tumors that are 
wild type for these genes [7, 12, 21]. We show here on a 
cohort of HGA enriched for midline and pediatric tumors 
that a commercially available rabbit polyclonal antibody 
directed against K27M mutant H3 variants can detect these 
mutations in fixed tissues using standard immunohisto-
chemistry with high sensitivity and specificity.
Materials and methods
Patient samples and pathological review
All samples were obtained with informed consent after 
approval of the Institutional Review Board of the respective 
B. Ellezam (*) 
Hopital Ste Justine, Montreal, QC, Canada
e-mail: Benjamin.ellezam@umontreal.ca
S. Albrecht (*) 
Montreal Children’s Hospital, Montreal, QC H3H1P3, Canada
e-mail: steffen.albrecht@hotmail.com
735Acta Neuropathol (2014) 128:733–741 
1 3
hospitals they were treated in, and were independently 
reviewed by pediatric neuropathologists (SA, BE, TP, 
AK, KL) according to the WHO guidelines. Samples were 
obtained from the Montreal Children’s Hospital (Montreal, 
McGill University Health Centre), University of Bonn 
(Bonn, Germany), Boston Children’s Hospital (Boston, 
Harvard University), Sainte-Justine Hospital (Montreal, 
Canada), University of Heidelberg (Heidelberg, Germany), 
and the Brain Tumor Toronto Bank (BTTB, Toronto). All 
samples were from formalin-fixed paraffin-embedded 
material. All midline pediatric HGA samples were from 
needle biopsies (pons) or partial resections (thalamus, 
spine, cerebellum) and most were obtained prior radio- 
and/or chemotherapy. Slides were available from individual 
tumor samples or from previously reported tissue microar-
rays (TMA) [6, 13, 20]. The pediatric HGA cohort (mean 
age 11 years) included tumor tissue from 124 WHO Grade 
IV astrocytomas (glioblastoma, GBM), 14 GBM recur-
rences, and 11 WHO Grade III astrocytomas (anaplastic 
astrocytoma, AA) (Table 1). A range of other brain tumors 
was also investigated and included other pediatric gliomas 
(n = 6), control brain (n = 8) and three TMAs containing, 
respectively, 97 medulloblastomas (MB), 71 primitive neu-
roectodermal tumors (PNET) samples, or 115 WHO Grade 
I (pilocytic astrocytomas, PA) (Supplementary Table 1). 
Clinical characteristics of patients with HGA are sum-
marized in Table 1. TMAs comprised an average of three 
tumor cores from the same sample with a mean diameter of 
1.5 mm for each core. Cores were selected from the origi-
nal tumor sample and oriented on the TMA by the neuro-
pathologist and controlled for adequate tumor representa-
tion by hematoxylin/eosin staining.
Automated immunohistochemistry
Tissue samples were cut at 5 µm, placed on SuperFrost/
Plus slides (Fisher) and dried overnight at 37 °C. The 
slides were then loaded onto a Discovery XT Autostainer 
(Ventana Medical System). All solutions used for auto-
mated immunohistochemistry were from Ventana Medical 
System unless otherwise specified. Slides underwent de-
paraffinization and heat-induced epitope retrieval (CC1 
pre-diluted solution Cat# 950-124) following stand-
ard protocol. Immunostaining for H3K27M mutant and 
H3K27me3 were performed using a heat protocol. Briefly, 
rabbit polyclonal anti-H3K27M (#ABE419 Millipore, 
1:500), or rabbit monoclonal anti-H3K27me3 (C36B11, 
#9733 Cell Signalling, diluted at 1:75) diluted in the anti-
body diluent (Cat# 251-018) were applied manually for 
32 min at 37 °C and then incubated using the appropriate 
detection kit (OmniMap anti-Rabbit-HRP, Cat# 760-4311) 
for 8 min, followed by ChromoMap-DAB Cat# 760-159). 
Omission of the primary antibody was used as negative 
control. Slides were then counterstained with hematoxylin 
for 4 min, blued with Bluing Reagent for 4 min, removed 
from the autostainer, washed in warm soapy water, dehy-
drated through graded alcohols, cleared in xylene, and 
mounted with Permount. Sections were analyzed by con-
ventional light microscopy. Immunohistochemistry for 
INI1 (clone 25/BAF47, 1:400, BD Biosciences) and 
CD45 (clone T29/33, pre-diluted, Dako) was performed 
according to the manufacturer’s instructions on a Dako 
autostainer. Slides were scanned using the Aperio system 
and independently scored for H3K27M and H3K27me3-
positive staining by three independent individuals includ-
ing two neuropathologists (SA, BE) blinded to the tumor 
genotype. Results were merged and consensus scoring was 
obtained as previously described [15, 20]. Briefly, samples 
were considered as positive for H3K27M staining if tumor 
cells showed nuclear staining and the core included a con-
trol blood vessel or normal brain with negative staining for 
the antibody. H3K27me3 staining was performed as previ-
ously described [23]. If no H3K27me3 or H3K27M stain-
ing were observed, we performed a control staining against 
a nuclear protein INI1 used as control for nuclear staining 
and tissue/fixation quality. Immunohistochemistry for INI1 
(clone 25/BAF47, 1:400, BD Biosciences) and double labe-
ling for H3K27me3 (DAB brown chromogen) and CD45 
(clone T29/33, pre-diluted, Dako, AP red chromogen) was 
performed according to the manufacturer’s instructions on 
Table 1  Clinico-pathological characteristics and tumor genotype of high-grade astrocytomas included in this study
GBM glioblastoma, AA anaplastic astrocytoma, M male, F female
a
 Includes recurrences
Diagnosis n Age median (range) Gender H3K27M genotypea




14 recurrences 8.7 ± 6.7
WHO grade III astrocytomas (AA) 11 10.2 ± 2.9 1 M, 9 F, 4 H3F3A
1 HIST1H3B
6 wild-type
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a Dako autostainer. Three HGA samples from our initial 
dataset were thus excluded based on negative INI1 stain-
ing. Notably, archival material fixed with Bouin’s solution 
showed a very strong background using the H3K27M anti-
body and poor H3K27me3 staining, and were therefore 
excluded from further analysis (n = 7, Supplementary 
Fig. 1a). Also, autopsy samples showed a high background 
when stained using the anti-H3K27M antibody and were 
not included in the dataset (Supplementary Fig. 1b).
DNA sequencing of H3 variants
For HGA samples not previously screened using whole 
exome/Sanger sequencing [8, 12, 20] high-resolution melt-
ing (HRM) or pyrosequencing were used as previously 
described [20]. Briefly, H3F3A and HIST1H3B mutation 
screening using HRM was performed on a Light Cycler 
480 using triplicates for each sample. Each reaction con-
tained 10 μl of LC480 High Resolution Master Mix 2× 
(Roche), 0.2 μM of each primer, 2.5 μM MgCl2, 5–20 ng 
of genomic DNA and water to a final volume of 20 μl. PCR 
conditions were as follows: 95 °C for 10 min followed by 
45–50 cycles of 95 °C for 10 s, a touchdown of 68–58 °C 
for 15 s (1 °C/cycle) and 72 °C for 15 s. Primers were 
HPLC-purified (Integrated DNA Technologies). MgCl2 
concentration was optimized for each reaction to give low 
Ct values and a high plateau phase. Primer sequences are 
H3F3A-F: 5′-GTACAAAGCAGACTGCCCGCAAAT-3′, 
H3F3A-R: 5′-GTGGATACATAC AAGAGAGACTTTG 
TCCC-3′, and Hist1H3B-F: 5′-ACAGACGTCTCTGCAGG 
CAAGC-3′ and Hist1H3B-R: 5′-GGCGGTAACGGTGAGG 
CTTT-3′. After amplification, the PCR product was dena-
tured at 95 °C for 1 min, cooled down to 40 °C to allow 
duplex formation, then high-resolution melting data were 
acquired when the temperature was increased from 70 to 
95 °C (1 °C/cycle—25 data acquisition per °C). Analysis 
was performed with the Light Cycler 480 Gene scanning 
software. Melting curves were first normalized, which were 
then shifted along the temperature, and finally a difference 
plot was generated. The grouping method chosen was the 
“In-run” standards where the software applies grouping on 
melting standard samples included in the run.
Results and discussion
We performed targeted sequencing using HRM or pyrose-
quencing to analyze the genotype of tumor and control 
brain samples included in this study for which informa-
tion on H3.1 (HIST31B and HIST31C) and H3.3 (H3F3A) 
mutational status at position K27 was not available. We 
identified a K27M substitution in 48 samples, 5 HGA car-
rying H3.1K27M (4 on HIST1B and 1 on HIST1C) and 43 
HGA with H3.3K27M. Six HGA cases had no available 
material to perform genotype analysis and were excluded 
from further analysis.
We then assessed H3K27M expression by IHC on the 
143 genotyped HGA (118 GBM, 14 GBM recurrences, 
11 AA, Table 1). Results were compared to H3K27me3 
staining on consecutive sections and to genomic data. 
Anti-H3K27 M antibody showed a strong nuclear stain-
ing of most tumor cells (>80 %) in all 48 samples with 
the H3K27M genotype (Fig. 1; Tables 1, 2). None of the 
H3K27M wild-type samples showed nuclear staining 
(Table 2; Fig. 1; Supplementary Fig. 2). Importantly, the 
antibody was able to recognize both H3.3 and H3.1 K27M 
mutant tumors (Fig. 2), as expected given that the peptide 
it was raised against is identical in both mutant H3 vari-
ants. The anti-H3K27M antibody did not stain any of the 
H3.3G34R/V HGA included in this dataset (n = 7). It did 
not recognize endothelial cells or other vascular struc-
tures within H3K27M mutant HGA which still expressed 
H3K27me3 (Fig. 1; Supplementary Fig. 2).
H3K27me3 staining was negative or strongly decreased 
in K27M mutant samples as previously described [2, 14, 
23], while tumor cells in samples wild type for H3K27M 
showed high expression of this post-translational histone 
modification (Fig. 1). Out of the 14 recurrent GBM, 3 
were genotyped to be H3K27M mutants. All three GBM 
showed strong H3K27M expression across most tumor 
cells. Conversely, recurrent samples wild type for this 
mutation showed no staining. This further confirms that 
when H3K27M is identified at diagnosis it is maintained by 
most tumor cells at relapse and is not acquired at the time 
of tumor recurrence similar to IDH-mutant gliomas [10]. 
To further assess the specificity of H3K27M antibody, we 
screened TMAs containing PA, MB and PNET samples and 
a set of other pediatric brain tumors or normal brain (Sup-
plementary Table 1). As expected, none of these samples 
had positive H3K27M staining (Supplementary Table 1, 
Supplementary Fig. 3 and data not shown).
A small number of samples (n = 6) wild type for 
H3K27M showed scattered cells with pale, nonspecific-
appearing cytoplasmic staining with the anti-H3K27M 
antibody, mostly in areas of necrosis or inflammation, but 
these cases were not viewed as equivocal and were not 
interpreted as positive by scoring pathologists blinded to 
the genotype. As for the anti-H3K27me3 antibody, some 
strong extravascular nuclear staining was seen in ~10 % 
of H3K27M mutant samples (which generally do not 
stain except in blood vessels). In some cases the staining 
appeared mainly to be from mononuclear inflammatory 
cells including microglia, which we confirmed by immu-
nostaining and co-immunostaining with anti-CD45, a 
marker that recognizes lymphocytes, on consecutive slides 
from the same tumors (Fig. 3). However, nuclear staining 
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for H3K27me3 in H3K27M samples could not be solely 
accounted for by CD45-positive cells, which highlights 
the fact that loss of H3K27me3 is not reliable to predict 
H3K27M genotype (Fig. 3b; Supplementary Fig. 4). In 
addition, based on the limits of IHC at the single cell level, 
we cannot exclude that a small subset of tumor cells is neg-
ative for both H3K27M and H3K27me3 in H3K27M tumor 
samples (Supplementary Fig. 4).
Fig. 1  Immunohistochemical (IHC) staining of pediatric high-grade 
astrocytomas (HGA) using the anti-H3K27M antibody correlates 
with tumor genotype and decreased H3K27Me3 in tumors. Repre-
sentative IHC of pediatric HGA using anti-H3K27M (a, c, e, g) or 
anti-H3K27me3 (b, d, f, h) antibodies and counterstained with hema-
toxylin. H3K27M shows strong nuclear positivity in tumor cells, but 
no staining in the nuclei of endothelial and smooth muscle cells in 
blood vessels in K27M mutant tumors (a, c). Tumors wild type for 
H3K27 show no nuclear staining with the anti-H3K27M antibody (e, 
g). Corresponding H3K27me3 staining on the same samples shows 
global decrease of the expression of this histone mark in H3K27M 
mutant tumors (b, d) compared to tumors wild type for this mutation 
(f, h). Notably, positivity for H3K27me3 was mainly seen in tumor 
vessels (b, d) even though a degree of intra-tumor staining was also 
seen in H3K27M mutant samples (d)
Table 2  Comparison between immunohistochemical analysis of 
H3K27M mutations and tumor genotype in high-grade astrocytomas 
included in this study
a
 Includes recurrences (3 H3K27M mutants and 11 wild types)




H3K27 wild type 0 84a
H3K27M 48a 0
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Our results indicate that the rabbit monoclonal antibody 
directed against H3K27M mutations specifically recog-
nizes mutant proteins using simple IHC. Nuclear immu-
nostaining was restricted to tumor cells in samples carrying 
the mutant H3K27M genotype, both in H3.1 and H3.3. 
This staining is more specific than H3K27me3 investiga-
tion as it specifically targets the mutation and not one of its 
downstream effects. Other pediatric posterior fossa tumors 
Fig. 2  Immunohistochemical (IHC) staining of H3.1K27M and 
H3.3K27M mutant high-grade astrocytomas (HGA) shows simi-
lar results using the anti-H3K27M and anti-H3K27me3 antibod-
ies. Representative sections from HGAs (WHO Grade III) carrying 
H3.3K27M (a, b) and H3.1K27M (c, d, e, f) immunostained with 
anti-H3K27M (a, c, e) and anti-H3K27me3 (b, d, f) antibodies. Two 
areas from the same H3.1K27M WHO Grade III DIPG sample are 
shown to further illustrate that the K27M mutation is also present in 
seemingly lower grade tumor sections (c)
Fig. 3  H3K27M staining and H3K27me3/CD45 co-immunostaining 
on consecutive slides of an H3K27M mutant high-grade astrocy-
toma. a anti-H3K27M staining (nuclear); b co-immunostaining using 
a CD45 antibody (cytoplasmic, purple) and an H3K27me3 antibody 
(nuclear, dark brown); results indicate that only a proportion of cells 
positive for H3K27me3 staining in H3K27M mutant high-grade 
astrocytomas are positive for CD45 staining and represent a lympho-
cytic infiltrate (light blue arrows). Endothelial and smooth muscle 
vascular cells show uptake of the H3K27me3 antibody alone (aster-
isk) while few cells within the tumor remain positive for H3K27me3 
(black arrow)
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including ependymomas [16] and different sub-groups of 
medulloblastomas [11, 17–19] have strong H3K27me3 
positive staining based on their own biology. In addition, 
based on the scattered H3K27me3-positive staining in sev-
eral mutant H3K27M HGA, interpretation of the results 
may prove challenging when using H3K27me3 expression 
levels as a surrogate marker of H3K27M. In summary, our 
data show that the H3K27M antibody is highly useful for 
tumor diagnosis in the clinical setting where IHC is rou-
tine procedure in pathology laboratories. This is especially 
true in the context of midline and hindbrain tumors where 
surgical material is limited. The concurrent use of this anti-
body with other known prognostic pediatric HGA markers 
including TP53 will help orient patients to optimal clinical 
care and management based on the very poor prognosis and 
limited survival seen in the context of this mutation.
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